samedan logo

 
 
spacer
home > pmps > summer 2017 > collaboration is crucial
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Collaboration is Crucial

This event took place in Brussels, Belgium, on 6-7 June 2017 in front of 100 top decision-makers within the pharmaceutical and logistics industries.

As the conference came to a close, audience members were invited to offer their thoughts on what the overall message had been based on the numerous presentations. The first response summarised the key focus of many of the presentations: “collaboration is the key.”

It was a fitting answer to conclude an event that had brought people together from around the world to engage with the biggest issues facing the supply chain. All stakeholders were represented, as delegates from airlines mingled with individuals from logistics companies, as well as the pharma and regulatory industries.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Weiss Technik UK Ltd provides secure cold storage of Coronavirus vaccine

Loughborough, 23rd November 2020 - The UK government has secured 40 million doses of the new Pfizer/BioNTECH vaccine. Once available, the vaccine doses will have to be transported and stored at -70 °C. This requires an uninterrupted cold chain. As a long-standing partner of the pharmaceutical industry and specialist for extreme temperatures, Weiss Technik UK Ltd offers suitable storage solutions for this.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement